Receptor.AI

Receptor.AI

Receptor.AI - Public relations

Targeting cryptic pockets with Receptor.AI drug discovery platform

Jun 9, 2023

Targeting cryptic pockets with Receptor.AI drug discovery platform

Jun 9, 2023

Receptor.AI - Public relations

AI-based prediction of small molecules’ selectivity for highly similar protein variants

May 16, 2023

AI-based prediction of small molecules’ selectivity for highly similar protein variants

May 16, 2023

Receptor.AI - Public relations

Benchmark of the AI-augmented structure-based activity and affinity prediction methods

combined by a smart consensus function

Apr 14, 2023

Benchmark of the AI-augmented structure-based activity and affinity prediction methods

Apr 14, 2023

Receptor.AI - Public relations

The key for fast and efficient drug discovery: benchmarking the Receptor.AI ADMET prediction model

Mar 31, 2023

The key for fast and efficient drug discovery: benchmarking the Receptor.AI ADMET prediction model

Mar 31, 2023

Receptor.AI - Public relations

The rock-solid base for Receptor.AI platform: benchmarking the drug-target interaction AI model

Mar 14, 2023

The rock-solid base for Receptor.AI platform: benchmarking the drug-target interaction AI model

Mar 14, 2023

Receptor.AI - Public relations

Identification of dual-targeting Mycobacterium tuberculosis aminoacyl-tRNA synthetase inhibitors…

Feb 7, 2023

Identification of dual-targeting Mycobacterium tuberculosis aminoacyl-tRNA synthetase inhibitors…

Feb 7, 2023

Receptor.AI - Public relations

Developing bifunctional protein degraders for difficult-to-drug proteins with the Receptor.AI

Jan 30, 2023

Developing bifunctional protein degraders for difficult-to-drug proteins with the Receptor.AI

Jan 30, 2023

Receptor.AI - Public relations

Receptor.AI introduces 3DProtDTA — the next generation drug-target interaction AI model

Model description and performance benchmarks.

Jan 18, 2023

Receptor.AI introduces 3DProtDTA — the next generation drug-target interaction AI model

Jan 18, 2023

Receptor.AI - Public relations

Receptor.AI’s end-to-end drug discovery platform avoids computational overkill and embraces…

The companies, which provide drug discovery services, deal with two different types of customer requests. One of them is a request to help…

Jan 8, 2023

Receptor.AI’s end-to-end drug discovery platform avoids computational overkill and embraces…

Jan 8, 2023

Receptor.AI - Public relations

The lipid membranes are druggable and available for AI-based drug design

Are the lipid membranes druggable?

Jan 8, 2023

The lipid membranes are druggable and available for AI-based drug design

Jan 8, 2023

Receptor.AI

Receptor.AI provides an AI-powered drug discovery platform for pharma, biotech and academia that covers the whole drug discovery pipeline in a scalable manner.

Connect with Receptor.AI

Editors

Receptor.AI Company

Official account of RECEPTOR.AI company. We make the cell membranes druggable to provide new treatments for cancer and cardiovascular diseases.

Semen Yesylevskyy

PhD, Doctor of Sciences, researcher in the area of molecular dynamics and drug discovery. CSO of Receptor.AI. https://t.me/semen_yesylevskyy

Receptor.AI - Public relations

Help

Status

About

Careers

Press

Blog

Privacy

Rules

Terms

Text to speech